News from other websites on Novartis India
Twelve stocks in focus in Wednesday morning trade
May 15, 2013 at 08:26 | Source: Economic Times
NEW DELHI: Indian markets are likely to trade in a range with a positive bias on Wednesday. The immediate support level for Nifty is around 5980. "The Nifty is expected to head lower till 5950. In this period the key support will be at around 5980 a...
Novartis India Q4 net dips 26% at Rs 24 cr
May 14, 2013 at 18:12 | Source: The Hindu BusinessLine
New Delhi, May 14: Drug firm Novartis India today reported a 25.82 per cent dip in its net profit to Rs 24.41 crore for the quarter ended March 31, 2013 as compared to the corresponding period in the previous fiscal.The company had posted a net prof...
Novartis India quarterly net profit plunges 26%, sets dividend at Rs 10
May 14, 2013 at 18:12 | Source: Financial Express
Drug firm Novartis India today reported a 25.82 per cent dip in its net profit to Rs 24.41 crore for the quarter ended March 31, 2013 over the corresponding period in the previous fiscal. The company had posted a net profit of Rs 32.91 crore for the...
Nifty opens flat after Monday's big drop, Ranbaxy down 3%
May 14, 2013 at 09:19 | Source: FirstPost
Indian markets opened flat this morning as investors remain cautious, though some recovery is expected after the plunge of last session.The Sensex opened about 20 points higher at 19715.04, while the Nifty opened 9 points higher at 59990.Some bargain...
3 students to represent India at Novartis biotech camp in Switzerland
May 13, 2013 at 17:06 | Source: The Hindu BusinessLine
Mumbai, May 13: Novartis India has announced the next edition of the Novartis Biotechnology Leadership Camp (BioCamp) taking place in Hyderabad from July 8-10, 2013. BioCamp is a seminar organised by Novartis that brings talented students from diver...
Novartis appoints Citigroup as broker for Indian entity share sale
May 09, 2013 at 19:02 | Source: Financial Express
Drug major Novartis India today said its Swiss promoter Novartis AG has appointed Citigroup Capital Markets as the broker for the proposed share sale to reduce stake in the Indian entity. "Novartis AG has appointed Citigroup Capital Markets India Pv...
How the Indian judgment on Novartis will reverberate across the world
Apr 03, 2013 at 20:10 | Source: FirstPost
Washington : What has Big Pharma companies’ pants on fire is not the loss of one patent for Novartis but the “contagion effect” of the Indian Supreme Court judgment that will reverberate through the rest of the developing world. The 112-page j...
From Apple to Novartis: Why some patents deserve to die
Apr 02, 2013 at 15:58 | Source: firstpost
Yesterdays Supreme Court judgment in the case of Novartis anti-cancer drug Glivec has given rise to calls for stronger patent protection in India. The multinational lobby is yelling blue murder, and Novartis Indias chief Ranjit Shahani has muttered d...
Pharma MNCs current spend on R D in India not significant
Apr 02, 2013 at 12:56 | Source: Economic Times
Following the Supreme Court order rejecting its patent plea on cancer drug Glivec, Novartis India said it would not invest on research and development (R&D) in India and move it to favourable destinations. This has triggered fears that the R&D scene ...
Drug R&D: Why India can easily ignore Novartis blackmail
Apr 02, 2013 at 12:20 | Source: FirstPost
Also see Why the rejection of Novartis patent plea is a huge victory for India “Investors want returns, but intellectual property environment is unfavourable in India. So, big pharmas would not want to invest (here),” Ranjit Shahani of Novartis ...
India's rejection of Novartis drug patent could reverberate
Apr 02, 2013 at 12:20 | Source: Indian Express
The Supreme Court's rejection of a patent for an improved version of a costly cancer drug by Novartis AG could have big implications for the world's largest drugmakers. The ruling, which was handed down on Monday, signals the latest shift in the worl...
Drug R&D: Why India can easily ignore Novartis blackmail
Apr 02, 2013 at 11:52 | Source: firstpost
Investors want returns, but intellectual property environment is unfavourable in India. So, big pharmas would not want to invest (here), Ranjit Shahani of Novartis India said yesterday, reacting to the Supreme Court order rejecting the Swiss drug maj...
Novartis sulks after Supreme Court Glivec verdict, says won't invest in India
Apr 02, 2013 at 10:02 | Source: Financial Express
Novartis India, a unit of the Swiss pharma major, which lost patent plea for cancer drug Glivec in the Supreme Court today, described the verdict as a "set back for original innovation", and said the company will not invest on R D in the country. No...
Novartis India shares hit one-year low, recover later
Apr 02, 2013 at 05:02 | Source: Business Today
Novartis India shares on Monday hit a one-year low on the Bombay Stock Exchange (BSE) after the Supreme Court dismissed parent firm Novartis AG's plea for getting its blood cancer drug patented in India.The Swiss pharma major lost a seven-year long ...
Apr 02, 2013 at 04:42 | Source: Calcutta Telegraph News
Mumbai, April 1: Novartis, the $56.7-billion Swiss pharmaceutical giant, has decided not to invest in research and development in India after the Supreme Court today dismissed its application for a 20-year patent on Glivec, its biggest selling pharm...
Novartis India says will continue to file for patents
Apr 02, 2013 at 04:30 | Source: firstpost
MUMBAI (Reuters) - Novartis India Ltd (NOIN.BO), a unit of Swiss drugmaker Novartis AG (NOVN.VX), will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of i...
Landmark judgment: No SC cure for Novartis patent pain
Apr 02, 2013 at 03:22 | Source: DNA India
In a landmark judgment, the Supreme Court has rejected the plea of Swiss drugmaker Novartis to patent Glivec, used to treat chronic myeloid leukemia, paving the way for other manufacturers to make and sell versions of the medicine. Novartis has been ...
Sensex gains on Infosys, L&T; Novartis India falls
Apr 02, 2013 at 03:15 | Source: firstpost
MUMBAI (Reuters) - The BSE Sensex edged higher in the first trading session of a new fiscal year, as Infosys gained on optimism about its fourth-quarter earnings, while Larsen & Toubro gained after winning a $1 billion power plant order.Although ...
Will hurt investments, says Novartis India chief
Apr 02, 2013 at 02:02 | Source: The Hindu BusinessLine
Mumbai, April 1: Does the Supreme Court’s dismissal of Novartis’ plea send out worrying signals that India does not protect original research and intellectual property? Will it spurn foreign companies looking to invest in local research?...
Novartis loses landmark India cancer drug patent case
Apr 02, 2013 at 02:00 | Source: firstpost
MUMBAI/NEW DELHI (Reuters) - India's top court dismissed Swiss drugmaker Novartis AG's (NOVN.VX) attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for loca...
From DJ EU Officials Spain Aid Cap Of 100 Bn Euros 'should Be Enough'
